These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7464559)

  • 1. Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia.
    Kashyap ML; Hynd BA; Robinson K; Gartside PS
    Metabolism; 1981 Feb; 30(2):111-8. PubMed ID: 7464559
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
    Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
    J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.
    Holdsworth G; Stocks J; Dodson P; Galton DJ
    J Clin Invest; 1982 Apr; 69(4):932-9. PubMed ID: 7076853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
    Schonfeld G; George PK; Miller J; Reilly P; Witztum J
    Metabolism; 1979 Oct; 28(10):1001-10. PubMed ID: 226830
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CII/CIII ratio of transferable apolipoprotein in primary and secondary hypertriglyceridemia.
    Erkelens DW; Mocking JA
    Clin Chim Acta; 1982 May; 121(1):59-65. PubMed ID: 7083594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia.
    Ghiselli G; Schaefer EJ; Zech LA; Gregg RE; Brewer HB
    J Clin Invest; 1982 Aug; 70(2):474-7. PubMed ID: 7096573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays.
    Bren ND; Rastogi A; Kottke BA
    Mayo Clin Proc; 1993 Jul; 68(7):657-64. PubMed ID: 8350639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
    Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
    J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoprotein pattern and decreased platelet function in type V hyperlipoproteinemia.
    Aviram M; Brook JG
    Isr J Med Sci; 1985 Nov; 21(11):898-904. PubMed ID: 4077486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2.
    Stocks J; Holdsworth G; Galton D
    Lancet; 1979 Sep; 2(8144):667-71. PubMed ID: 90760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe hypertriglyceridaemia associated with altered apolipoprotein C and E composition of the triglyceride-rich lipoproteins.
    Stalenhoef AF; Demacker PN; Lutterman JA; Van't Laar A
    Neth J Med; 1981; 24(4):145-51. PubMed ID: 7279085
    [No Abstract]   [Full Text] [Related]  

  • 13. Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia.
    Stalenhoef AF; Demacker PN; Lutterman JA; van't Laar A
    Diabetologia; 1982 Jun; 22(6):489-91. PubMed ID: 7106445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haplotypes identified by DNA restriction-fragment-length polymorphisms in the A-1 C-III A-IV gene region and hypertriglyceridemia.
    Stocks J; Paul H; Galton D
    Am J Hum Genet; 1987 Aug; 41(2):106-18. PubMed ID: 2887109
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary evaluation of the usefulness of determination of apolipoprotein B. cholesterol and VLDL triglyceride concentrations in the early diagnosis of type IV hyperlipoproteinemia].
    Bobilewicz D; Kotlicka J; Grajnert K
    Pol Tyg Lek; 1981 Mar; 36(9):325-6. PubMed ID: 7267451
    [No Abstract]   [Full Text] [Related]  

  • 17. Chylomicron-like particles in severe hypertriglyceridemia.
    Aviram M; Sechter Y; Brook JG
    Lipids; 1985 Apr; 20(4):211-5. PubMed ID: 3999928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of apolipoproteins E and C in type V hyperlipoproteinemia.
    Kuusi T; Taskinen MR; Solakivi T; Kauppinen-Mäkelin R
    J Lipid Res; 1988 Mar; 29(3):293-8. PubMed ID: 3379342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia.
    Parhofer KG; Richter WO; Schwandt P
    Horm Metab Res; 1990 Nov; 22(11):589-94. PubMed ID: 2272605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.